Regulus Therapeutics Inc (RGLS NASDAQ) stock market data APIs
$1.3688
-0.1(-6.8%)
as of March 14, 2025
Regulus Therapeutics Inc Financial Data Overview
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Prev. Close
1.4681
Open
1.3688
High
1.5605
Low
1.3593
52 wk Range
0.8301-3
Market Cap
96 940 K
Shares Outstanding
65 500 K
Revenue
5 000 K
EPS
-0.2
Beta
1.412
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Regulus Therapeutics Inc data using free add-ons & libraries
Get Regulus Therapeutics Inc Fundamental Data
Regulus Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 000 K
- EBITDA: -49 693 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-19
- EPS/Forecast: -0.2225
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regulus Therapeutics Inc News
New
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
SAN DIEGO, July 18, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SAN DIEGO, June 27, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
SAN DIEGO, June 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
